A 24-week, Phase 2B, randomized, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the safety and efficacy of switching subjects from recombinant human erythropoietin to GSK1278863, allowing titration to achieve a hemoglobin target, in haemodialysis-dependent subjects with anaemia associated with chronic kidney disease.

Trial Profile

A 24-week, Phase 2B, randomized, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the safety and efficacy of switching subjects from recombinant human erythropoietin to GSK1278863, allowing titration to achieve a hemoglobin target, in haemodialysis-dependent subjects with anaemia associated with chronic kidney disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Daprodustat (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 11 Oct 2014 Trial status changed from recruiting to active, no longer recruiting, according to United Kingdom Clinical Research Network record.
    • 12 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top